Adaptive Biotechnologies is the pioneer and leader in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors.
They bring the accuracy and sensitivity of immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. They are also committed to translating immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care.
*Based on Preferred Stock Price, Adaptive Biotechnologies does not have a stock symbol since it is currently private and is yet to have an IPO.
EquityZen does not have an affiliation with, formal relationship with, or endorsement from the companies featured above.
These profiles are based on publicly available information and are intended to be informative in nature.
To learn more about whether you're eligible, typical investment size, company valuation, and share price, request access here.
Have a question or need support? We're here to help! Send us a quick message and we'll get right back to you.
Thanks you for your message - we'll contact you shortly.